title: Drotrecogin alpha (activated) in neonatal septic shock.
abstract: A 12-d-old neonate suffering from group B streptococcal septic shock was treated with 24 microg/kg/h recombinant human activated protein C [rhAPC, drotrecogin alpha (activated)] for 96 h. The protein C activity increased from 5% to 53% after rhAPC infusion. The patient recovered within 14 d without any adverse effects.
authors.affiliation: Division of Neonatology, Department of Paediatrics, University of Heidelberg Medical School, Heidelberg, Germany. david_frommhold@med.uni-heidelberg.de
authors.forename: David
authors.initials: D
authors.lastname: Frommhold
authors.forename: Alexandra
authors.initials: A
authors.lastname: Birle
authors.forename: Otwin
authors.initials: O
authors.lastname: Linderkamp
authors.forename: Eugen
authors.initials: E
authors.lastname: Zilow
authors.forename: Johannes
authors.initials: J
authors.lastname: Pöschl
mesh_terms: D000890:Anti-Infective Agents / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008586:Meningitis, Pneumococcal / Q000150:complications; D011486:Protein C / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012772:Shock, Septic / Q000188:drug therapy*; D013290:Streptococcal Infections / Q000188:drug therapy*; D013292:Streptococcus agalactiae
chemical_list: D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated